- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Treatment Updates in Recurrent C Difficile Infections
Paul Feuerstadt, MD, FACG, AGAF, discusses how antibiotics remain the initial treatment for Clostridioides difficile infections, but due to limited efficiency and recurrence rates, newer therapies including fecal microbiota transplantation (FMT), Rebyota (a purified live biotherapeutic), and Vowst (an oral microbiota therapeutic) have emerged as FDA-approved options that restore gut microbiome diversity and show promising efficiency in preventing recurrent infections, particularly in patients who have failed standard antibiotic therapy.
EP. 1: The Role of Testing for C Difficile in Clinical Practice
November 26th 2024Paul Feuerstadt, MD, FACG, AGAF, discusses how testing for Clostridioides difficile is recommended for hospitalized patients or outpatients with new-onset, unexplained diarrhea who have risk factors such as recent antibiotic use, hospitalization, or older age, and how empiric treatment should be initiated while awaiting test results if there is high clinical suspension.
Watch
EP. 2: Utilizing Antibiotics in Treatment of C Difficile
November 26th 2024The panelist discusses how antibiotics are paradoxically both the primary treatment for Clostridioides difficile infections and a major risk factor for recurrence since they disrupt the protective gut microbiome, which led to the development of alternative therapies like fecal microbiota transplantation to restore microbial balance and prevent reinfection.
Watch
